Healthy Clinical Trial
Official title:
Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor - a Randomized, Partly Double-blind Placebo-controlled Clinical Trial
Verified date | July 2018 |
Source | Daacro |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to assess whether intake of Glycine (MSG) leads to an increase of cognitive performance after an acute stressor compared to placebo. One group will receive verum, one group placebo and one group will not receive any intervention. Cognitive testing will be performed in connection with the Trier Social Stress Test (TSST).
Status | Completed |
Enrollment | 90 |
Est. completion date | June 15, 2018 |
Est. primary completion date | March 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - subject signs the informed consent to participate in the study - normally stressed subjects as verified by the TICS questionnaire with scores >3 and <37 Exclusion Criteria: - smoker - any known allergies to the test substances - lactose intolerance - any known addiction to drugs and/or alcohol - hyper- or hypotension (except for those whose blood pressure is stable using medication for more than 3 months) - known hyper- or hypothyroidism unless treated and under control (stable for more than 3 months) - any known current/acute or chronic physical or psychological diseases besides minor medical conditions (e.g. seasonal allergies) - intake of any medication which may affect the cognitive performance (e.g. psychotropics, sedating or stimulating medication) - any color vision impairment (e.g. red-green deficiency) - intake of dietary supplements or homoeopathic remedies during 2 weeks before V1 or during the study conduction - consumption of alcohol during 2 days before V1 or during the study conduction - excessive caffeine consumption (>400 mg caffeine/day or >= 4 cups of caffeinated coffee) - on a strict diet or practicing sport, extensively - attending an exam one week before and after the study participation - subjects having previously participated in the TSST - employee of the sponsor or Contract Research Organisation (CRO) - Investigator doubts truthfulness of self-reported health information - not suitable because of limited verbal and cognitive abilities |
Country | Name | City | State |
---|---|---|---|
Germany | daacro GmbH & Co. KG | Trier | Rhineland-Palatinate |
Lead Sponsor | Collaborator |
---|---|
Daacro | OOO MNPK BIOTIKI |
Germany,
File SE, Fluck E, Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. J Clin Psychopharmacol. 1999 Dec;19(6):506-12. — View Citation
Gundersen RY, Vaagenes P, Breivik T, Fonnum F, Opstad PK. Glycine--an important neurotransmitter and cytoprotective agent. Acta Anaesthesiol Scand. 2005 Sep;49(8):1108-16. Review. — View Citation
Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci. 1999 Jun;113(3):420-30. — View Citation
Olver JS, Pinney M, Maruff P, Norman TR. Impairments of spatial working memory and attention following acute psychosocial stress. Stress Health. 2015 Apr;31(2):115-23. doi: 10.1002/smi.2533. Epub 2014 Jan 3. — View Citation
Schoofs D, Preuss D, Wolf OT. Psychosocial stress induces working memory impairments in an n-back paradigm. Psychoneuroendocrinology. 2008 Jun;33(5):643-53. doi: 10.1016/j.psyneuen.2008.02.004. Epub 2008 Mar 21. — View Citation
Schwabe L, Wolf OT. Stress and multiple memory systems: from 'thinking' to 'doing'. Trends Cogn Sci. 2013 Feb;17(2):60-8. doi: 10.1016/j.tics.2012.12.001. Epub 2013 Jan 2. Review. — View Citation
Schwartz BL, Hashtroudi S, Herting RL, Handerson H, Deutsch SI. Glycine prodrug facilitates memory retrieval in humans. Neurology. 1991 Sep;41(9):1341-3. — View Citation
Shields GS, Sazma MA, McCullough AM, Yonelinas AP. The effects of acute stress on episodic memory: A meta-analysis and integrative review. Psychol Bull. 2017 Jun;143(6):636-675. doi: 10.1037/bul0000100. Epub 2017 Apr 3. Review. — View Citation
Shields GS, Sazma MA, Yonelinas AP. The effects of acute stress on core executive functions: A meta-analysis and comparison with cortisol. Neurosci Biobehav Rev. 2016 Sep;68:651-668. doi: 10.1016/j.neubiorev.2016.06.038. Epub 2016 Jun 28. Review. — View Citation
Shields GS, Trainor BC, Lam JC, Yonelinas AP. Acute stress impairs cognitive flexibility in men, not women. Stress. 2016 Sep;19(5):542-6. doi: 10.1080/10253890.2016.1192603. Epub 2016 Jun 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | TICS | Do Trier Inventory for Chronic Stress (TICS) scores differ between groups? The TICS includes 57 items. Stress chronicity is measured by the frequency of stressful events perceived retrospectively within the last 3 months. Answers are given on a five-point rating scale, where 0 resembles "never" and 4 "very often". For analysis the questionnaire items are assigned to 10 scales: Work overload (range 0-32), Social overload (0-24), Pressure to succeed (0-36), Work dissatisfaction (0-32), excessive demands at work (0-24), Lack of social recognition (0-16), Social stress (0-24), Social isolation (0-24) and Chronic worrying (0-16); the last scale presents a Screening scale for chronic stress (0-48). Scores are obtained by summing up the values of the scale specific questionnaire items. | Baseline | |
Other | STAI-trait | Do State Trait Anxiety Inventory (STAI) trait scores differ between groups? The STAI-trait measures anxiety as a personality trait and comprises 20 items. Answers are given on a four-point rating scale ranging from 1 = "almost never" to 4 = "almost always". Some STAI questions relate to the absence of anxiety, and are reversely scored. For analysis of the STAI-scale, items are combined in one scale, which then informs about trait anxiety. The score range is 20-80; higher scores indicate more anxiety. | Baseline | |
Other | Mental arithmetic performance during the TSST | Efficacy of the intake of Glycine (MSG) on arithmetic performance compared to placebo and control group. One part of the Trier Social Stress Test (TSST) is a mental arithmetic task. The subject is asked to stepwise subtract 17 from 2023 as quickly and correctly as possible. Performance will be measured by counting how many numbers the subject enumerates and how many times the subject has to restart. Furthermore, the lowest correct number and the shortest run will be recorded. | 37.5 minutes after first product intake | |
Other | eCB levels | Exploration of endocannabinoid levels (eCB) | 45, 10 minutes before first product intake, 28, 46, 55 minutes after first product intake, 10, 20, 35 and 50 minutes after second product intake | |
Other | Blood Glucose levels | Exploration of blood glucose levels | 75 minutes before first product intake, 25 and 46 minutes after first product intake | |
Primary | Delayed memory performance after the TSST (correct words) | Efficacy of the intake of Glycine (MSG) on performance in the Verbal Learning and Memory Test (VLMT) delayed recall task (number of correct words) compared to placebo and control group | 20 minutes after second product intake | |
Secondary | Delayed memory performance before and during the TSST | Efficacy of the intake of Glycine (MSG) on performance in the Verbal Learning and Memory Test (VLMT) delayed recall task (number of correct words, number of perseverations and wrong words) compared to placebo and control group | 15 minutes before and 42 minutes after first product intake | |
Secondary | Immediate memory performance before and after the TSST | Efficacy of the intake of Glycine (MSG) on Performance in the Verbal Learning and Memory Test (VLMT) immediate recall task (number of correct words, decreased number of perseverations and wrong words) compared to placebo and control group | 44 minutes before, 13 and 48 minutes after first product intake | |
Secondary | VAS stress | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute stress compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | VAS anxiety | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute anxiety compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | VAS insecurity | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute insecurity compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | VAS sleepiness | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute sleepiness compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | VAS tension | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute tension compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | VAS lack of energy | Efficacy of the intake of Glycine (MSG) on subjective evaluation of acute lack of energy compared to placebo and control group measured on a Visual Analogue Scale (VAS). The VAS is a 10cm bipolar visual scale ranging from "not at all" to "highly". VAS scores are obtained by using a ruler and measuring the position of the participant's mark with millimeter precision. To control for possible variations due to printing, the total length of the line is also measured and percentage scores for each subject are computed. Percentage scores range from 0-100. | 20 minutes, 37 minutes and 46 minutes after first product intake | |
Secondary | STAI-state | Efficacy of the intake of Glycine (MSG) on state anxiety as measured by the State Trait Anxiety Inventory (STAI) compared to placebo and control group. The STAI-state measures anxiety as a temporary emotional state and comprises 20 items. Answers are given on a four-point rating scale ranging from 1 = "not at all" to 4 = "very true". Some STAI questions relate to the absence of anxiety, and are reversely scored. For analysis of the STAI-scale, items are combined in one scale, which then informs about state anxiety. The score range is 20-80; higher scores indicate more anxiety. | 20 minutes and 46 minutes after first product intake | |
Secondary | Systolic and diastolic blood pressure | Efficacy of the intake of Glycine (MSG) on blood pressure in response to the TSST compared to placebo and control group | 25 minutes and 46 minutes after first product intake | |
Secondary | Delayed memory performance after the TSST (perseverations, wrong words) | Efficacy of the intake of Glycine (MSG) on performance in the Verbal Learning and Memory Test (VLMT) delayed recall task (decreased number of perseverations and wrong words) compared to placebo and control group | 20 minutes after second product intake | |
Secondary | Cognitive performance before and after the TSST (Stroop) | Efficacy of the intake of Glycine (MSG) on performance in the Stroop test (speed and accuracy) compared to placebo and control group | 10 minutes before first product intake and 23 minutes after second product intake | |
Secondary | Cognitive performance before and after the TSST (CogTrack) | Efficacy of the intake of Glycine (MSG) on performance in attention, working memory, learning and recognition tasks of CogTrack compared to placebo and control group | 40 minutes before first product intake, immediately after second product intake | |
Secondary | Heart rate | Efficacy of the intake of Glycine (MSG) on heart rate in response to the TSST compared to placebo and control group | Continous measurement starting 10 minutes after first product intake and ending 10 minutes after second product intake | |
Secondary | Salivary Cortisol | Efficacy of the intake of Glycine (MSG) on salivary cortisol raw values in response to the TSST compared to placebo and control group | 45, 10 minutes before first product intake, 28, 46, 55 minutes after first product intake, 10, 20, 35 and 50 minutes after second product intake |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |